Results 31 to 40 of about 4,251 (181)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Journal of Hematology & Oncology, 2022
Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension.
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison   +17 more
doaj   +1 more source

Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib [PDF]

This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years).
Bajwa, N, Sharman, JP, Miranda, P, Ghia, P, Rule, S, Shaw, B, Seymour, JF   +6 more
core   +2 more sources

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib [PDF]

Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations.
Benrashid, Samon, Byrd, John C, Lai, Tzung-Huei, Munugalavadla, Veerendra, Robak, Tadeusz, Jurczak, Wojciech, Woyach, Jennifer A, Rule, Simon, Lai, Richard, Illés, Árpád, Mohamed, Nehad, Jones, Daniel, Kater, Arnon P, Seymour, John F, Ghia, Paolo, Long, Susan, de Bruin, Gerjan, De Jesus, Gary   +17 more
core   +2 more sources

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data

Cancer Management and Research, 2020
Krista Isaac,1 Anthony R Mato2 1Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence: Krista ...
Isaac K, Mato AR
doaj  

Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling

Pharmaceuticals, 2021
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median duration of survival of approximately 14 months after diagnosis. High resistance to chemotherapy remains a major problem.
Yu-Kai Su, Oluwaseun Adebayo Bamodu, I-Chang Su, Narpati Wesa Pikatan, Iat-Hang Fong, Wei-Hwa Lee, Chi-Tai Yeh, Hsiao-Yean Chiu, Chien-Min Lin   +8 more
doaj   +1 more source

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies

Frontiers in Oncology, 2021
The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chronic lymphocytic
Sining Zhu, Sining Zhu, Jaeyong Jung, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale, Samantha Gokhale, Ping Xie, Ping Xie   +9 more
doaj   +1 more source

Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States

, 2023
Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib. A semi-Markov model with three health states (progression-free, progressed disease, and death)
Priyanka Gaitonde (15203357), Kellie Ryan (8595495), Bengt Liljas (15203354), Victoria Genovez (15203348), Talha Munir (3520109), Victor Genestier (15203351)   +5 more
core   +1 more source

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma [PDF]

The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely ...
Patti Caterina, Belada David, Morawska Marta, Chu Michael P, Cheah Chan Y, Salek David, Dreyling Martin, Kryachok Iryna, Forsyth Cecily, Zhang Jingyang, Rule Simon, Fogliatto Laura, Sancho Juan-Manuel, Borbényi Zita, Ramadan Safaa, Kollaborációs szervezet: ECHO investigators, Kahl Brad S, Song Yuqin, Paludo Jonas, Jurczak Wojciech, Li Yufu, Wang Michael, Lesley Robin   +22 more
core   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +1 more source